MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Syndax Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

13.25 1.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.9

Max

13.3

Chiffres clés

By Trading Economics

Revenu

-10M

-94M

Ventes

-4.8M

7.7M

BPA

-1.1

Marge bénéficiaire

-1,226.159

Employés

270

EBITDA

-5.3M

-89M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+163.08% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-295M

1B

Ouverture précédente

11.48

Clôture précédente

13.25

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Syndax Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 juil. 2024, 12:35 UTC

Principaux Mouvements du Marché

Syndax Pharma Shares Fall Premarket After FDA Extends Revumenib Review

Comparaison

Variation de prix

Syndax Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

163.08% hausse

Prévisions sur 12 Mois

Moyen 34.2 USD  163.08%

Haut 51 USD

Bas 16 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

11

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

10.83 / N/ASupport & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.